NCT01629082View on ClinicalTrials.gov

Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

June 6, 2012

Primary Completion Date

October 27, 2015

Study Completion Date

June 27, 2018

Conditions

Myeldysplastic Syndrome (MDS)Chronic Myelomonocytic LeukemiaBone Marrow DiseasesNeutropeniaAcute Myeloid Leukemia (AML)

Interventions

DRUG

Clofarabine

DRUG

Lenalidomide

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH